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Abstract. The objective of this study is to determine
whether pergolide therapy is an effective modality for the
de novo treatment of patients with macroprolactinomas.
Twenty-two consecutive patients with macroprolactinomas
were included in the study and followed prospectively.
These included 16 men and 6 women in whom pregnancy
was not of concern. Pergolide was administered once or
twice a day depending on the patient’s preference. Ten
patients received 0.1 mg daily as a maintenance regimen
and in the others the daily dose ranged from 0.05 to 0.5 mg.
Eight patients reported minor but tolerable side effects.
One patient had to be switched to cabergoline because of
intolerable nausea. After a mean  of  12  months (range,
3–36), mean PRL levels declined from 3,135 ng/ml (range,
126–31,513) to 50 ng/ml (3–573), representing a mean PRL
suppression of 88% (range, 0–99). PRL levels became nor-
mal in 15 patients and decreased to 25–40 ng/ml in 3 others.
The mean tumor volume shrinkage was 25% or greater in 19
patients (86%), 50% or greater in 17 patients (77%), and
75% or greater in 10 patients (45%). Visual abnormalities
were reversible after pergolide therapy in all but 1 of 12
patients with initially abnormal formal visual testing. Two
out of 4 premenopausal women did not normalize PRL lev-
els and had persistent oligomenorrhea. Testosterone was
low in 14 men at presentation and normalized in 3 with
pergolide therapy. We conclude that pergolide is a safe,
inexpensive, and generally well-tolerated dopamine agonist
for the treatment of macroprolactinomas in men and women
in whom pregnancy is not of concern. In these speci~c
populations, pergolide may become the ~rst-line therapy
for treatment of macroprolactinomas.
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Introduction
PRL-secreting pituitary adenomas account for 60% of
all functioning-pituitary tumors. Patients with macro-
prolactinomas (10 mm) are often men or post-
menopausal women who come to medical attention
with manifestations of tumor mass effect such as visual
~eld defects, headaches, or hypopituitarism. Patients
with macroprolactinomas require therapy to achieve
PRL normalization, tumor shrinkage, and reversal of
visual abnormalities or  pituitary dysfunction. These
objectives are usually effectively accomplished medi-
cally by using dopamine agonists. Transsphenoidal
adenomectomy is currently recommended only when
patients are intolerant of or resistant to these medica-
tions. Bromocriptine and cabergoline are the only
dopamine agonists approved in the United States for
the treatment of prolactinomas [1].
Bromocriptine normalizes PRL levels in 70–80%
and signi~cantly decreases adenoma size and restores
gonadal function in 60–80% of patients with macropro-
lactinomas [2,3]. Almost 40% of the patients, however,
are either resistant or intolerant to bromocriptine [4].
Likewise, because of its very short half-life, bromo-
criptine needs to be administered up to three times per
day, reducing patient’s compliance.
Cabergoline is a selective, potent and long-lasting
dopamine agonist that is at least as effective as bro-
mocriptine in lowering PRL levels and shrinking tu-
mor  size  but with  signi~cantly  less  side effects [5].
Cabergoline, with a once or twice weekly dosing, nor-
malizes PRL levels in 61–100%, signi~cantly decreases
adenoma size in 65–100%, and restores gonadal func-
tion in 80–90% of patients with macroprolactinomas
[6–9]. Pergolide is a long-acting, less expensive, ergot
derivative that effectively suppresses PRL secretion
for more than 24 hours [10], allowing control of hyper-
prolactinemia with only one daily dose [11], therefore,
facilitating patients’ compliance. Pergolide is currently
approved for the treatment of Parkinson’s disease
where it is administered at much higher doses than
those used for prolactinomas. There is a paucity of data
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in the literature concerning tumor shrinkage with per-
golide therapy in patients with macroprolactinomas.
The majority of reports have included very few pa-
tients, reduction in adenoma size has not been ade-
quately evaluated, and most patients have previously
received other dopamine agonists, radiotherapy, or
have had pituitary surgery [12–17] confounding the
interpretation of the results. A recent paper with ade-
quate clinical, hormonal, and radiological follow up, in-
cluding 18 patients who received pergolide as ~rst-line
therapy, showed excellent results after a mean of 27.4
months of therapy [18]. We report our experience in 22
macroprolactinoma patients who received pergolide as
primary therapy and con~rm its effectiveness in nor-
malizing PRL levels, reducing tumor size, and improv-




Thirty-seven patients attending our Pituitary and
Neuroendocrine Center because of PRL-secreting pi-
tuitary tumors have been treated with pergolide. Pa-
tients with  macroprolactinomas (10  mm) in whom
pergolide was used as primary therapy were included
in this report (n  22). Patients who did not meet the
above inclusion criteria (n  13) or were lost to follow
up (n  2) were excluded from the study.
Study design
Complete clinical history, physical and ophthalmologic
examination, PRL, testosterone (in men), and FT4 lev-
els were obtained during the ~rst visit. These were
repeated one to three months later and at least yearly
thereafter. Cortisol and IGF-1 levels were measured at
baseline. Plasma gonadotropins were measured in
postmenopausal women. Dedicated pituitary MRI was
done at baseline, between 2 and 6 months after initia-
tion of pergolide therapy and annually thereafter. The
MRI protocol included coronal, sagittal, and axial scans
centered at the pituitary region performed before and
after administration of gadolinium DPTA. Formal vis-
ual testing was carried out in all patients who pre-
sented with clinically-apparent visual abnormalities (n
 6) and in 6 other patients without visual complaints
but in whom the pituitary adenoma was too close to the
optic chiasm to rule out its subclinical compromise. In
patients with no distortion of the optic chiasm on the
MRI, who had no visual complaints and whose clinical
assessment of visual ~elds was normal, no formal visual
~eld study was performed. Pergolide was started at a
dose of 0.025 mg at night, and the dose was increased
gradually as tolerated with the goal of achieving a PRL
level as close to the normal range as possible. Pergolide
was  administered  as either one or two daily doses,
depending on patients’ preference. Tumor volume was
calculated as 4/3pr1r2r3, where r1, r2, and r3 were maxi-
mal vertical, lateral and anteroposterior radii, respec-
tively.
All hormone measurements were performed in the
Ligand laboratory at the University of Michigan Medi-
cal Center, using commercially available kits.
Results
Patient characteristics
Table 1 shows demographic data of 16 men and 6 women
included in the study. Mean age in men was 41 yr (range,
16–68) and in women was 48 yr (range, 39–64). The
symptom that led to the diagnosis of macroprolactinoma
in men was visual loss in 5, headache in 3, short stature
in 1, and erectile dysfunction in 1. In 6 men the tumor
was incidentally found in CT or MRI scans performed
for other reasons. All premenopausal women (n  4)
presented with oligo/amenorrhea and/or galactorrhea.
One each of the postmenopausal women presented with
visual loss and headache.
Pergolide therapy
The initial treatment dose of pergolide ranged from 0.1
to 0.75 mg per day. Patient 14 was admitted to the
hospital for initiation of pergolide, 0.25 mg three times
per day because of the severity of his symptoms re-
lated to a giant prolactinoma. The most common per-
golide maintenance dose was 0.1 mg per day (n  10),
with others ranging between 0.05 and 0.5 mg daily. The
median dose of pergolide was also 0.1 mg per day. Nine
patients reported side effects related to pergolide
theraphy. Side effects were minor and easily tolerable
and included stuffy nose (n  5), postural lighthead-
ness (n  2), nausea (n  2), emotional lability (n  1),
headache (n  1), mood changes (n  1), and tremor (n
 1). In the vast majority of cases, these side effects
tended to decrease in intensity or to vanish altogether
with time. Only patient 13 developed intolerable nau-
sea after increasing pergolide to 0.4 mg per day, requir-
ing a switch to cabergoline. MRI scans and hormonal
evaluations in this patient were done while on per-
golide. No patient experienced apparent cerebrospinal
_uid leak during treatment.
PRL normalization
Mean initial PRL level for all patients was 3,135 ng/ml
(range, 126–31,513).  Three patients had  initial PRL
levels lower than 200 ng/ml but their tumors shrank by
40% or greater with pergolide therapy, arguing against
these tumors being non-secreting pituitary adenomas
with stalk compression. PRL levels became lower than
50 ng/ml within 6 months in 11 patients and within 12
months in 15 patients. After a mean of 12 months
(range, 3–36), mean PRL level declined to 50 ng/ml
(range, 3–573), representing a mean PRL suppression
of 88% (range, 0–99). PRL levels became normal (3–25
ng/ml) in 15 patients and decreased to 25–40 ng/ml in 3
others. PRL suppression was 90% or greater in 17 of
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22 patients. Patients 3 and 4 had tumor shrinkages of
42 and 36%, respectively, despite the fact that PRL
levels were almost unchanged. Patient 17 had an al-
most complete disappearance of the tumor with 93%-
PRL suppression, although PRL was still mildly ele-
vated 7 months after initiation of pergolide. Only
patient 15 can be considered a therapeutic failure in
terms of both PRL suppression and tumor shrinkage.
Tumor shrinkage
Table 2 shows tumor characteristics. The mean initial
maximal tumor diameter was 2.9 cm (range, 1.2–5.5).
All the tumors but 3 were greater than 2 cm in maximal
diameter and 11 tumors were 3 cm or greater. Eleven
and 15 patients had tumor size reductions greater than
50% within 6 and 12 months after initiation of per-
golide, respectively. The mean ~nal maximal tumor di-
ameter was 1.8 cm (range, 0–4.2). Eleven tumors were
smaller than 2 cm and 20 were 3 cm or smaller after
pergolide  therapy. Overall, the  mean  tumor  volume
shrinkage was 67% (range, 9–100). Tumor shrinkage
was 25% or greater in 19 patients, 50% or greater in 17
patients, and 75% or greater in 10 patients. Although
patient 10 had only 9%-tumor shrinkage with pergolide
therapy, his PRL level became normal suggesting ade-
quate response to pergolide. Likewise, patient 24 nor-
malized  PRL levels with 99%-PRL suppression,  al-
though tumor size reduction was 24% after 4 months of
Table 1.
PRL Pergolide T
Patient Initial Final Supp. Duration Dose Initial Final
# Gender Age ng/ml ng/ml % months mg/day ng/ml ng/ml
1 F 64 3,894 13.4 99 12 0.1
2 F 40 523 7.7 99 9 0.1
3 F 44 156 103 34 36 0.05
4 F 39 549 573 0 19 0.1
5 F 63 2,178 10 99 20 0.1
6 F 39 360 4 99 13 0.05
7 M 36 1,834 2.5 99 23 0.1 1.52 2.16
8 M 38 247 33 87 5 0.25 1.71 4.51
9 M 56 126 11.4 90 3 0.1 0.31 1.45
10 M 36 1,617 6.1 90 7 0.5 0.97 0.96
11 M 44 5,245 2.5 99 26 0.05 0.1 on T
12 M 68 799 3.8 99 23 0.1 3.42 7.33
13 M 46 179 33 82 5 0.4 1.64 on T
14 M 32 31,513 4.3 99 6 0.25 0.77 on T
15 M 54 555 101 78 23 0.3 0.1 on T
16 M 26 5,796 15 99 3 0.2 1.89 5.41
17 M 41 2,397 71 93 7 0.25 0.91 on T
18 M 16 595 22 96 5 0.2 0.14 0.49
19 M 39 2,355 40 98 3 0.1 1.08 1.06
20 M 53 1,519 8 99 4 0.2 1.15 2.5
21 M 24 3,249 19 99 3 0.1 2.7 2.57
22 M 49 3,290 25 99 3 0.1 0.01 on T
PRL supp  prolactin suppression. T  testosterone
Table 2.
First MRI Last MRI
Patient (VLAP) (VLAP) Shrinkage
# cm cm %
1 3.03.13.0 1.21.22.1 89
2 2.32.31.8 0.70.71.2 94
3 0.81.20.9 0.80.90.7 42
4 1.11.81.0 1.01.40.9 36
5 2.52.52.5 0* 100
6 2.53.02.8 2.02.02.2 59
7 1.92.11.7 0.41.00.4 97
8 1.61.81.5 0.60.91.5 81
9 2.22.01.8 1.41.51.6 58
10 2.02.31.8 1.92.21.8 9
11 4.34.44.3 2.33.72.6 73
12 1.52.11.8 1.10.90.9 84
13 2.72.92.8 2.02.02.4 56
14 5.55.24.2 2.14.23.1 77
15 2.03.01.5 2.02.51.5 17
16 3.03.82.4 0.80.81.0 98
17 3.02.72.2 0.81.00.8 96
18 2.72.71.9 1.82.21.5 57
19 3.22.21.8 2.21.61.2 68
20 2.63.12.2 2.22.92.1 24
21 3.02.13.1 1.92.02.2 57
22 4.13.54.1 0* 100
V  maximal vertical diameter.
L  maximal lateral diameter.
AP  maximal antero-posterior diameter.
*  no tumor identi~ed.
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pergolide therapy. Figure 1 shows the MRI scans from
patient 22.
Visual ~elds
Six patients came to medical attention because of visual
~eld defects. These and 6 other patients (n  12) under-
went formal visual testing, which was abnormal in all
patients who presented with visual loss and in 4 of the
patients who did not. Visual abnormalities were com-
pletely reversible in all patients except patient 17 who
had a residual left superior temporal quadrant defect.
Gonadal function
All premenopausal women (n  4) presented with oligo/
amenorrhea and/ or galactorrhea. Patients 2 and 6 nor-
malized PRL levels with resumption of normal menses.
Patients 3 and 4 did not normalize PRL levels, and
irregular menstrual periods persisted. Patient 1 was
postmenopausal but gonadotropins remained inappro-
priately low after one year of pergolide therapy, despite
normalization of PRL. Patient 5 had physiological ele-
vation of gonadotropins to the postmenopausal range
within 6 months of pergolide treatment. By history 10 of
16 men had decreased libido and/or erectile dysfunction
for months to years before the diagnosis of macropro-
lactinoma was established, included two patients with
normal testosterone at presentation. Initial testoster-
one levels were low in 14 men and normalized in only 3
patients with pergolide therapy. Testosterone levels
were transiently lower in 6 men after starting pergolide
therapy, including patient 21 whose baseline testoster-
one was normal but came down temporarily below the
normal range. None had a ~nal testosterone lower than
the initial testosterone levels. Six men received testos-
terone replacement therapy.
Discussion
We have con~rmed in this open label study that per-
golide is a very effective primary therapy for the treat-
ment of macroprolactinomas in men and women. This
~nding along with the excellent tolerance of pergolide,
its lower cost, and the once-a-day-dosing schedule sug-
gest that this medication may be considered ~rst line
therapy in patients with macroprolactinomas.
In this study, PRL normalization after  pergolide
therapy was achieved in 15 patients (68%) and PRL
levels between 25–40 ng/ml in 3 others. Previous studies
have suggested that bromocriptine and pergolide are
equally effective in lowering PRL levels in patients
with hyperprolactinemia [13,15,17], although only a few
patients with macroprolactinomas were included. Al-
though direct comparison between cabergoline and per-
golide has not been performed, cabergoline has been
found to normalize PRL levels in 61–100% of patients
with macroprolactinomas [6,7,9,19] similar to the 68%
success rate with pergolide [18] and this study.
We found that a mean of 12 months of pergolide ther-
apy caused a mean tumor shrinkage of 67%. All patients
but 3 (86%) had tumor volume reductions greater than
25%. A previous study of tumor shrinkage in patients
with macroprolactinomas has shown that 4 of 6 patients
on pergolide and 1 of 6 patients on bromocriptine had
25% or greater reductions in adenoma size [17]. Overall,
bromocriptine signi~cantly decreases adenoma size in
almost 80% of patients with macroprolactinomas [3].
Similarly, cabergoline has been found to signi~cantly
reduce tumor volume in 65–100% of patients with
macroprolactinomas [6,7,9,19], compared to 67–95% of
patients on pergolide [14,17,18]. In only one report that
Fig. 1. Sagittal gadolinium-enhanced T1 weighted pituitary
magnetic resonance image before (a) and 3 months after (b)
pergolide therapy (patient 22). Figure 1a shows a 4.1  3.5 
4.1-cm sellar mass with suprasellar and sphenoidal sinus ex-
tension with cystic and hemorrhagic components. Fig. 1b
shows complete disappearance of the mass with normal appear-
ance of the pituitary gland.
a
b
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included 3 patients with macroprolactinomas, tumor
size did not change with pergolide administration, but
those patients had been previously resistant to other
dopamine agonists [16].
Visual ~eld defect amelioration usually precedes or
parallels the radiological tumor  shrinkage. If visual
~elds remain compromised after tumor shrinkage de-
spite adequate optic chiasm decompression, subsequent
surgical tumor debulking will not add any bene~t [20].
In our series, of 10 patients with visual disturbances at
presentation, all but 1 (90%) had visual ~eld defects
improvement. This ~gure is similar to that reported
with bromocriptine [21] and cabergoline [6,9].
Hypogonadism in patients with macroprolactinomas
may be secondary to hyperprolactinemia per se or to
gonadotrope dysfunction due to  compression or de-
struction by the tumor. It is dif~cult to determine before
treatment whether gonadal dysfunction is temporary
or permanent, and only the response to therapy pro-
vides a ~nal answer. If PRL normalization is not accom-
panied by resumption of normal menstrual periods or
elevation of gonadotropin levels in pre and postmeno-
pausal women, respectively, or by testosterone normali-
zation in men, permanent gonadotrope damage is prob-
ably present. Three out of 6 women in our series
recovered their gonadotrope  function. On the  other
hand, bromocriptine restores ovulatory menses in
80–90% of women with hyperprolactinemia, although
most of them have microprolactinomas; and cabergoline
restores normal menses in 75–80% of women with
macroprolactinomas [6,7]. Fourteen men had low tes-
tosterone levels at presentation (87%). Patients who
normalized testosterone levels with pergolide therapy
(n  3) or who were placed on testosterone replacement
therapy (n  6) had marked improvement in energy
level, sexual function, libido, and body hair growth. A
previous study suggested that cabergoline was initially
more  effective than bromocriptine  in improving go-
nadal and sexual function and fertility in men with
macroprolactinomas, although by 6 months there was
no difference in those parameters [22]. Freda et al [18]
found that pergolide therapy improved symptoms of
hypogonadism in 83% of men with macroprolactinomas,
although testosterone levels were normalized in only 6
of 15 of them. The low rate of testosterone normalization
in our series may be related to the shorter period of
follow up in our report compared to that study [18],
because initial tumor size and tumor shrinkage is simi-
lar in both studies. Six of the men in this study had a
transient fall in testosterone levels shortly after per-
golide initiation, which has been previously reported
[14,18], although their ~nal testosterone levels were
either unchanged or higher. This fall in testosterone
levels despite PRL suppression and tumor shrinkage
may be related to the fact that dopamine agonists may
inhibit gonadotropin release [23,24].
Both bromocriptine and cabergoline are expensive.
Contacts with several local pharmacies revealed that
the average monthly cost of these drugs is approxi-
mately $210 and $300 for bromocriptine and cabergoline
at customarily recommended doses of 7.5 mg daily and 1
mg weekly, respectively. In contrast, monthly cost of
pergolide 0.1 mg daily is about $80. Also pergolide has
signi~cantly less side effects than bromocriptine, allow-
ing us to switch successfully 9 patients (not included in
this study) to pergolide because of bromocriptine intol-
erance. Similar to a previous report [18], only one pa-
tient in our series had to be switched from pergolide to
cabergoline because of side effects. Even though the
teratogenic potentials of bromocriptine and cabergoline
are exceedingly low [25,26], the current recommenda-
tions mandate interruption of these drugs in young
women as soon as the diagnosis of pregnancy is estab-
lished. Since the formal analysis of teratogenicity of
pergolide has not been performed, we do not prescribe
this medication to young women with reproductive po-
tential. The premenopausal women in this study were
either surgically sterilized or sexually inactive and
warned against the possibility of pregnancy.
In conclusion, pergolide is a safe, effective, and usu-
ally well tolerated dopamine agonist that can be used
as primary therapy for the treatment of macroprolact-
inomas in men and women in whom pregnancy is not of
concern. In addition, pergolide is less expensive than
the other two dopamine agonists available in the
United States and, unlike bromocriptine, can be admin-
istered once daily. Therefore, pergolide may be the
~rst line therapy for patients with macroprolactinomas
in these speci~c populations.
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